950 — Lee's Pharmaceutical Holdings Share News
0.000.00%
Last trade - 00:00- HK$624.17m
- HK$330.52m
- HK$1.44bn
Brief: Lee's Pharmaceutical Says Got Medical Device Registration Certificate For Inomax Dsir Plus Delivery System
Brief: Lee's Pharmaceutical Sees Unaudited Net Profit Attributable Between HK$40 And HK$90Mln For Year
Brief: Lee's Pharmaceutical Announces Inclusion Of Treprostinil Injection, Teglutik And Trittico In NRDL
Brief: Lee's Pharmaceutical Reports Qtrly Profit Attributable HK$34.2 Mln
Brief: Lee's Pharmaceutical Says Investigational New Drug Candidate Approved By U.S. FDA
Brief: Lee's Pharmaceutical Says Obtained Drug Marketing Authorisation Of Azilsartan Tablets From NMPA On Sept 20
Brief: Lee's Pharmaceutical Says Qtrly Profit Attributable HK$8.2 Mln
Brief: Lee's Pharmaceutical Says Got Global License Of Surfaxintm, Surfaxin LSTM And Aerosurftm
Windtree surges on licensing deal for lung disease therapy
Brief: Lee's Pharmaceutical Holdings Ltd Sees Net Profit Attributable Of Between Hk$25 Million And Hk$30 Million For Six Months
Brief: Unicycive Announces Exclusive License And Development Agreement With Lee’S Pharmaceutical Holdings Limited For Renazorb In China And Certain Other Asian Markets
Brief: Lee's Pharmaceutical Says Drug Registration Certificate For Teglutik Obtained From China's Nmpa
Brief: Lee's Pharmaceutical Says Drug Registration Certificate For Natulan Obtained From China's Nmpa
Brief: Lee's Pharmaceutical FY Profit Attributable HK$1.99 Bln
Brief: Lee's Pharmaceutical Holdings Says Qtrly Revenue Of HK$368.3 Mln
Brief: Lee's Pharmaceutical Says NDA Of Socazolimab Submitted, Accepted By China's NMPA
Brief: Lee's Pharmaceutical Obtained Approval From CDE Of China's NMPA For Socazolimab
Brief: Lee's Pharmaceutical Reports Qtrly Profit Attributable of HK$2.11 Bln
Brief: Lee's Pharmaceutical Holdings Ltd Sees Increase In Net Profit Attributable Six Months